WallStreetZenWallStreetZen

NASDAQ: OBIO
Orchestra Biomed Holdings Inc Stock Forecast, Predictions & Price Target

Analyst price target for OBIO

Based on 2 analysts offering 12 month price targets for Orchestra Biomed Holdings Inc.
Min Forecast
$14.00+72.2%
Avg Forecast
$17.00+109.1%
Max Forecast
$20.00+146%

Should I buy or sell OBIO stock?

Based on 2 analysts offering ratings for Orchestra Biomed Holdings Inc.
Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their OBIO stock forecasts and price targets.

OBIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-06-12
lockedlocked$00.00+00.00%2024-01-19

1 of 1

Forecast return on equity

Is OBIO forecast to generate an efficient return?
Company
-70.09%
Industry
73.55%
Market
80.58%
OBIO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is OBIO forecast to generate an efficient return on assets?
Company
-48.51%
Industry
31.45%
OBIO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

OBIO earnings per share forecast

What is OBIO's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$1.58
Avg 2 year Forecast
-$1.69
Avg 3 year Forecast
-$1.49

OBIO revenue forecast

What is OBIO's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$3.2M+43.95%
Avg 2 year Forecast
$4.0M+81.23%
Avg 3 year Forecast
$2.9M+31.54%
OBIO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

OBIO revenue growth forecast

How is OBIO forecast to perform vs Biotechnology companies and vs the US market?
Company
14.52%
Industry
37.21%
Market
10.62%
OBIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
OBIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

OBIO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
OBIO$8.13$17.00+109.10%Strong Buy
AVIR$3.43N/AN/A
INO$11.31$23.67+109.26%Buy
JSPR$19.10$76.00+297.91%Strong Buy
MGNX$4.70$11.86+152.28%Buy

Orchestra Biomed Holdings Stock Forecast FAQ

Is Orchestra Biomed Holdings Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: OBIO) stock is to Strong Buy OBIO stock.

Out of 2 analysts, 2 (100%) are recommending OBIO as a Strong Buy, 0 (0%) are recommending OBIO as a Buy, 0 (0%) are recommending OBIO as a Hold, 0 (0%) are recommending OBIO as a Sell, and 0 (0%) are recommending OBIO as a Strong Sell.

If you're new to stock investing, here's how to buy Orchestra Biomed Holdings stock.

What is OBIO's earnings growth forecast for 2024-2026?

(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.03%.

Orchestra Biomed Holdings's earnings in 2024 is -$51,643,000.On average, 3 Wall Street analysts forecast OBIO's earnings for 2024 to be -$56,663,927, with the lowest OBIO earnings forecast at -$59,766,790, and the highest OBIO earnings forecast at -$52,966,976. On average, 3 Wall Street analysts forecast OBIO's earnings for 2025 to be -$60,600,662, with the lowest OBIO earnings forecast at -$71,576,994, and the highest OBIO earnings forecast at -$54,756,400.

In 2026, OBIO is forecast to generate -$53,145,918 in earnings, with the lowest earnings forecast at -$56,903,710 and the highest earnings forecast at -$49,388,126.

What is OBIO's revenue growth forecast for 2024-2026?

(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual revenue growth rate of 14.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.21%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.62%.

Orchestra Biomed Holdings's revenue in 2024 is $2,216,000.On average, 2 Wall Street analysts forecast OBIO's revenue for 2024 to be $114,165,305, with the lowest OBIO revenue forecast at $110,944,341, and the highest OBIO revenue forecast at $117,386,270. On average, 3 Wall Street analysts forecast OBIO's revenue for 2025 to be $143,726,604, with the lowest OBIO revenue forecast at $98,418,367, and the highest OBIO revenue forecast at $178,942,485.

In 2026, OBIO is forecast to generate $104,323,469 in revenue, with the lowest revenue forecast at $29,704,453 and the highest revenue forecast at $178,942,485.

What is OBIO's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: OBIO) forecast ROA is -48.51%, which is lower than the forecast US Biotechnology industry average of 31.45%.

What is OBIO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year OBIO price target, the average OBIO price target is $17.00, with the highest OBIO stock price forecast at $20.00 and the lowest OBIO stock price forecast at $14.00.

On average, Wall Street analysts predict that Orchestra Biomed Holdings's share price could reach $17.00 by Jun 12, 2025. The average Orchestra Biomed Holdings stock price prediction forecasts a potential upside of 109.1% from the current OBIO share price of $8.13.

What is OBIO's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: OBIO) Orchestra Biomed Holdings's current Earnings Per Share (EPS) is -$1.48. On average, analysts forecast that OBIO's EPS will be -$1.58 for 2024, with the lowest EPS forecast at -$1.67, and the highest EPS forecast at -$1.48. On average, analysts forecast that OBIO's EPS will be -$1.69 for 2025, with the lowest EPS forecast at -$2.00, and the highest EPS forecast at -$1.53. In 2026, OBIO's EPS is forecast to hit -$1.49 (min: -$1.59, max: -$1.38).

What is OBIO's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: OBIO) forecast ROE is -70.09%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.